Recombinant and Subunit Vaccine

A recombinant or subunit vaccine presents only a defined part of a pathogen, typically a purified protein antigen, rather than the whole organism. Recombinant DNA technology is used to express the chosen antigen in a host such as yeast, bacterial, or insect cells, sometimes assembled into virus-like particles, giving a highly defined product that cannot cause infection but often requires adjuvants and boosters to achieve durable immunity.

Definition

A recombinant or subunit vaccine is an immunising preparation containing one or more defined pathogen antigens, commonly proteins produced by recombinant DNA expression, rather than the whole organism, used to induce a targeted protective immune response.

Scope

This entry covers how recombinant and subunit antigens are produced and formulated, why a defined-component approach is used, and the immunological trade-offs of presenting an isolated antigen. It is a platform-level reference within vaccine types and does not provide schedules, dosing, or individual immunisation advice.

Core questions

• How is a defined antigen produced by recombinant DNA technology for use in a vaccine?
• Why does presenting an isolated component, rather than a whole pathogen, change the immune response?
• What roles do adjuvants, virus-like particles, and antigen presentation play in boosting immunogenicity?
• What safety and consistency advantages follow from a highly defined product?

Key concepts

• Recombinant DNA expression of antigens
• Subunit (single-component) antigen
• Virus-like particles
• Defined, well-characterised composition
• Adjuvants
• Booster doses
• Cannot cause infection

Mechanisms

The gene encoding a selected protective antigen is cloned and expressed in a production host so that the purified protein, or self-assembling virus-like particles built from it, can be formulated as the vaccine. Because only a defined component is presented and it cannot replicate, the immune stimulus is precise but may be less intrinsically immunogenic than a whole organism; adjuvants are therefore commonly added to enhance and direct the response, particle display can improve recognition, and booster doses help build durable antibody levels. The result is a highly characterised product whose composition is consistent from batch to batch and which cannot cause the infection it protects against.

Clinical relevance

Recombinant and subunit vaccines are established components of immunisation, having been used against pathogens for which a defined protein or particle antigen confers protection, including the first recombinant yeast-derived hepatitis B vaccine and virus-like-particle vaccines against human papillomavirus. This entry describes the platform and its immunology; specific products, schedules, and eligibility follow current guidance and are outside its scope.

Evidence & guidelines

Randomised trials and decades of programmatic use support recombinant and subunit vaccines for their indicated diseases, and the platform's design principles are summarised in vaccinology reviews. Product-specific recommendations are set by the World Health Organization and national immunisation advisory bodies.

History

The recombinant subunit era began in the 1980s, when recombinant DNA technology made it possible to express a pathogen antigen in a heterologous host and purify it as a vaccine, exemplified by the recombinant yeast-derived hepatitis B vaccine. Subsequent virus-like-particle vaccines, such as those against human papillomavirus, extended the approach to self-assembling antigen particles.

Key figures

• Maurice Hilleman
• Ian Frazer
• Martin Bachmann

Seminal works

• mcaleer-1984
• garland-2007
• bachmann-jennings-2010

Frequently asked questions

How is a recombinant vaccine different from an inactivated vaccine?

An inactivated vaccine uses the whole killed pathogen, whereas a recombinant or subunit vaccine uses only a defined component, usually a protein antigen produced by recombinant DNA technology, giving a more precisely characterised product that cannot cause infection.

Why do many subunit vaccines include an adjuvant?

Because an isolated antigen is often less immunogenic than a whole organism, adjuvants are added to strengthen and shape the immune response, and booster doses are frequently used to achieve durable protection.